CRISPR Therapeutics reported strong second-quarter 2026 financial results, driven by significant growth in its blockbuster gene-edited therapy CASGEVY. The company generated $76 million in revenue for the quarter, representing a 78% increase from the previous quarter and a 151% year-over-year surge. This momentum was bolstered by the FDA's recent approval of CASGEVY for children as young as two years old with sickle cell disease or transfusion-dependent beta thalassemia, expanding the eligible patient population to approximately 5,500 individuals.
Beyond its commercial success, CRISPR Therapeutics advanced multiple in vivo and ex vivo pipeline programs. The company initiated Phase 1 clinical trials for CTX340 targeting refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency using its proprietary SyNTase editing platform. Additionally, development continues on CTX310 for severe hypertriglyceridemia and refractory hypercholesterolemia, with a late-breaking abstract accepted for presentation at the European Society of Cardiology Congress in August 2026.
Financially, the company strengthened its balance sheet with $2.36 billion in cash, cash equivalents, and marketable securities as of June 30, 2026, up from $1.98 billion a year prior. This increase was primarily fueled by $585 million in proceeds from convertible senior notes issued in March 2026. While the company reported a net loss of $91.2 million for the quarter, this represents a substantial improvement compared to the $208.5 million loss recorded in the same period last year, reflecting improved operational efficiency and revenue recognition.
The press release also highlighted progress in its autoimmune and immuno-oncology portfolios, including the allogeneic CAR-T cell therapy zugo-cel and siRNA-based programs like CTX611 for thromboembolic diseases. Strategic collaborations with Vertex Pharmaceuticals and Sirius Therapeutics continue to support development and commercialization efforts globally, positioning CRISPR Therapeutics as a diversified leader in gene editing technologies.
📈 CASGEVY revenue hit $76M in Q2 2026, up 151% year-over-year.
✅ FDA approved CASGEVY for sickle cell disease in children aged 2+.
💰 Cash and securities totaled $2.36 billion as of June 30, 2026.
📉 Net loss narrowed to $91.2 million in Q2 2026 from $208.5M.
🤝 Vertex collaboration leads global CASGEVY development on a 60/40 basis.
📈 CASGEVY revenue reached $76 million in Q2 2026, marking a 78% quarter-over-quarter and 151% year-over-year increase.
✅ FDA approved CASGEVY for children aged 2 and older with sickle cell disease or transfusion-dependent beta thalassemia, expanding the addressable market.
🧬 Phase 1 clinical trials initiated for CTX340 (refractory hypertension) and CTX460 (alpha-1 antitrypsin deficiency).
💰 Cash, cash equivalents, and marketable securities totaled $2.36 billion as of June 30, 2026.
📉 Net loss narrowed to $91.2 million in Q2 2026 from $208.5 million in the same quarter last year.
🔬 CTX310 (ANGPTL3) development continues in Phase 1b trials for severe hypertriglyceridemia and refractory hypercholesterolemia.
🤝 Collaboration with Vertex Pharmaceuticals leads global development and commercialization of CASGEVY on a 60/40 basis.
🧬 Zugo-cel (CTX112) advancing in Phase 1 trials for autoimmune diseases including lupus, sclerosis, and multiple sclerosis.
🩸 CTX611 (FXI inhibitor) advancing through Phase 2 trials for thromboembolic disorders with potential broad indications.
📈 Analysts maintained or upgraded ratings, with Citi raising its price target to $88 citing CASGEVY momentum.
Bullish Signals
- Q2 revenue surged $76M, up 78% QoQ and 151% YoY.
- FDA approval expands eligible pediatric population to ~5,500 children.
- $2.36B cash position funds pipeline development and commercialization.
- Net loss decreased to $91.2M from $208.5M prior year.
- Phase 1 trials for CTX340/CTX460 expand SyNTase technology.
Risk Factors
- Net loss of $91.2 million this quarter.
- Global reimbursement efforts for CASGEVY remain ongoing.
- Early Phase 1 trials for CTX340 and CTX460 pending.
Bullish Signals
- CASGEVY revenue surged to $76 million in Q2 2026, driven by a 78% quarter-over-quarter and 151% year-over-year growth.
- FDA approval for CASGEVY in children as young as two years old significantly expands the eligible patient population to approximately 5,500 individuals.
- Strong cash position of $2.36 billion provides ample liquidity to fund pipeline development and commercialization efforts.
- Net loss decreased substantially to $91.2 million from $208.5 million in the prior year quarter, indicating improving financial trajectory.
- Initiation of Phase 1 trials for CTX340 and CTX460 demonstrates successful expansion into new therapeutic areas using proprietary SyNTase technology.
- CTX310 program continues to advance with a late-breaking abstract accepted for presentation at the European Society of Cardiology Congress.
- Strategic collaborations with Vertex and Sirius Therapeutics provide shared resources and global commercialization reach.
Risk Factors
- Company reported a net loss of $91.2 million for the quarter, though this is an improvement over the previous year.
- Ongoing efforts to secure sustainable reimbursement globally for CASGEVY remain underway in various markets.
- Clinical trials for investigational candidates like CTX340 and CTX460 are still in early Phase 1 stages with long-term outcomes yet to be determined.
CRISPR Therapeutics reported financial results and a business update for the second quarter ended June 30, 2026. CEO Samarth Kulkarni highlighted strong execution across the portfolio, noting continued momentum for CASGEVY following FDA approval for children as young as two years old. The company also expanded its in vivo pipeline by initiating Phase 1 clinical trials for CTX340 targeting refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency.
The press release details the company's diversified portfolio, including its strategic collaboration with Vertex Pharmaceuticals for CASGEVY, where Vertex leads global development and commercialization while profits are shared on a 60/40 basis. CRISPR Therapeutics is advancing proprietary in vivo liver editing programs using its SyNTase technology to treat cardiovascular diseases like familial hypercholesterolemia and hypertension.
Additionally, the company is developing Zugocabtagene geleucel (zugo-cel), an allogeneic CAR T cell therapy for autoimmune diseases and hematologic malignancies. A collaboration with Sirius Therapeutics focuses on siRNA-based programs, specifically CTX611, a long-acting inhibitor of coagulation factor XI intended to provide anticoagulant effects with reduced bleeding risk.
📅 CRISPR Therapeutics reported Q2 2026 results on August 3, 2026.
✅ CASGEVY FDA approved for children as young as 2 years old.
🤝 Vertex leads global development under a 60/40 profit-sharing agreement.
🧬 Phase 1 trials initiated for CTX340 and CTX460 therapies.
💉 Advancing in vivo liver editing using proprietary SyNTase technology.
📅 CRISPR Therapeutics reported Q2 2026 financial results and provided a business update on August 3, 2026.
✅ CASGEVY momentum continues with FDA approval extended to children as young as 2 years old for sickle cell disease and transfusion-dependent beta thalassemia.
🧬 Phase 1 clinical trials were initiated for CTX340 (refractory hypertension) and CTX460 (alpha-1 antitrypsin deficiency).
🤝 Vertex Pharmaceuticals leads global development and commercialization of CASGEVY under a 60/40 profit-sharing agreement.
💉 CRISPR Therapeutics is advancing in vivo liver editing programs using its proprietary SyNTase technology for cardiovascular indications.
🧬 Zugocabtagene geleucel (zugo-cel) advances as an allogeneic CAR T cell therapy for autoimmune diseases and oncology.
🩸 Collaboration with Sirius Therapeutics develops CTX611, a long-acting siRNA targeting coagulation factor XI.
Bullish Signals
- CASGEVY expands to pediatric patients as young as two years old.
- Phase 1 trials initiated for new programs CTX340 and CTX460.
- Strategic collaborations with Vertex and Sirius Therapeutics diversify pipeline.
Bullish Signals
- CASGEVY demonstrates strong market momentum with regulatory expansion to include pediatric patients as young as two years old.
- The company successfully initiated Phase 1 clinical trials for two new in vivo programs, CTX340 and CTX460, expanding its therapeutic reach.
- Strategic collaborations with Vertex and Sirius Therapeutics provide a diversified pipeline spanning gene editing and siRNA technologies.
CRISPR Therapeutics AG (NASDAQ: CRSP) is highlighted as a biotech stock with significant upside potential, ranking 8th on a list of 12 top picks compiled by Insider Monkey as of January 15, 2025. The article notes that while 2024 was challenging for the sector, experts like Johan Hueffer of Novo Holdings and John Flood of Goldman Sachs believe conditions are improving. Hueffer observed that capital raising difficulties have eased in recent quarters, while Flood pointed out that biotech stocks offer an "option-like structure" due to their sensitivity to interest rates and reliance on future profits. This sensitivity is particularly relevant following the Federal Reserve's rate cuts since September, which reduced the benchmark borrowing rate to a 4.25%-4.5% target range by January 8, 2025, with market expectations for further cuts in 2025 adjusted downward.
The company, headquartered in Zug, Switzerland, utilizes its proprietary CRISPR/Cas9 platform to develop gene-based medicines for serious diseases such as oncology, rare diseases, and regenerative medicine. A major catalyst for CRSP is the FDA approval and global launch of CASGEVY, a gene therapy for sickle cell disease and transfusion-dependent beta-thalassemia in patients aged 12 and older, which has received regulatory clearance in markets including Canada, Switzerland, Great Britain, and the European Union. As of September 30, 2024, CRISPR Therapeutics maintains a robust financial position with approximately $1.9 billion in cash, cash equivalents, and marketable securities, providing the liquidity needed to advance its clinical trial portfolio across autoimmune, diabetes, and cardiovascular indications.
Despite these positive fundamentals, Goldman Sachs data indicates that the biotechnology sector remains under-owned by hedge funds, ranking in the 13th percentile for long/short positioning over the past year and the 4th percentile over the last five years. Insider Monkey suggests that investors can potentially outperform the market by imitating top hedge fund picks, citing their quarterly newsletter strategy which has returned 275% since May 2014, significantly beating its benchmark. However, the article concludes with a caveat that while CRSP holds promise, the authors maintain greater conviction in AI stocks for delivering higher returns over shorter timeframes, directing readers to separate reports on AI investments and dividend stocks from companies like Nike, McDonald's, and JPMorgan Chase.
📈 JPMorgan and Novo see biotech poised for upside after 2024.
🏦 Goldman Sachs notes biotech offers option-like structure with rate cut potential.
📉 Fed lowered rates to 4.25%-4.5% range in early January.
📊 Biotech remains under-owned by hedge funds at 13th percentile.
🧬 CRISPR Therapeutics holds $1.9B cash and ranks 8th for upside.
📈 JPMorgan and Novo Holdings view biotech stocks as poised for considerable upside following a challenging 2024 and improving capital-raising trends.
🏦 Goldman Sachs highlights that biotech offers an "option-like structure" with significant potential due to sensitivity to the Federal Reserve's recent rate cuts.
📉 The Fed reduced its benchmark borrowing rate to a 4.25%-4.5% range in early January, though it lowered its outlook for future rate cuts in 2025.
📊 Goldman Sachs data indicates the biotech sector remains under-owned by hedge funds, ranking in the 13th percentile for long/short positioning over the past year.
🧬 CRISPR Therapeutics AG (CRSP) utilizes a proprietary CRISPR/Cas9 platform to develop gene-based medicines for serious diseases like oncology and rare disorders.
✅ The FDA approved CASGEVY, a gene therapy for sickle cell disease and beta-thalassemia, which has gained regulatory approval in multiple countries including the EU and UK.
💰 As of September 30, 2024, CRISPR Therapeutics holds a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities.
🔬 The company is strategically advancing its clinical trial portfolio across autoimmune, diabetes, oncology, and cardiovascular indications for 2025 expansion.
🏆 CRSP ranks 8th on a list of 12 biotech stocks selected for having the highest analyst upside potential as of January 15, 2025.
🤖 The article notes that while CRSP has strong potential, the authors maintain greater conviction in AI stocks for delivering higher returns within a shorter timeframe.
Bullish Signals
- FDA approved CASGEVY for ages 12+.
- Regulatory approvals advancing in Canada, UK, EU.
- Gene therapy launches for sickle cell disease.
Bullish Signals
- CRISPR Therapeutics AG (CRSP) has received FDA approval and launched CASGEVY, a gene therapy for sickle cell disease and beta-thalassemia in patients 12 years and older, creating considerable momentum with regulatory approvals underway in Canada, Switzerland, Great Britain, the European Union, and others.
Amova Asset Management Americas Inc. reduced its stake in CRISPR Therapeutics AG by 5.3% during the first quarter, selling 104,236 shares and holding approximately 1.85 million shares valued at $88.19 million. The position represents about 1.2% of Amova's total holdings and ranks as its 26th largest position. Several other major institutional investors have adjusted their positions in the stock recently, with GSK plc initiating a new stake worth roughly $168.89 million in the fourth quarter.
Orbis Allan Gray Ltd increased its CRISPR Therapeutics holding by 76.9% in the second quarter to own 2.76 million shares valued at $134.47 million, while State Street Corp lifted its position by 35.6% to hold 3.27 million shares worth $159.08 million. ARK Investment Management LLC grew its stake by 7.5% in the fourth quarter, now owning over 10.5 million shares valued at $551.78 million, and Norges Bank acquired a new position valued at approximately $25.71 million.
Insider Naimish Patel sold 3,786 shares for a total value of $210,577 to cover tax withholding obligations related to the vesting of equity awards, reducing his personal holding by 16.36%. Following this transaction, he retains 19,357 shares valued at approximately $1.08 million. Company insiders collectively own 5.20% of CRISPR Therapeutics stock. The article also notes recent quarterly earnings results showing a loss per share of $1.28 and revenue of $1.46 million for the quarter.
CRISPR Therapeutics is a biopharmaceutical company developing gene-editing therapies using its proprietary CRISPR/Cas9 platform to treat serious diseases through ex vivo and in vivo applications. Its lead program, CTX001, is an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent beta-thalassemia in collaboration with Vertex Pharmaceuticals. The company currently has a market capitalization of $4.53 billion and a negative price-to-earnings ratio of -7.55.
📉 Amova Asset Management trimmed stake by 5.3% to $88.19 million value.
📈 ARK Investment holds largest position with 10.52 million shares worth $551.78 million.
💰 Company insiders collectively own 5.20% of CRISPR Therapeutics stock.
📊 Q1 loss per share was $1.28 on revenue of $1.46 million.
🧬 Lead program CTX001 treats sickle cell disease and beta-thalassemia with Vertex.
📉 Amova Asset Management Americas Inc. trimmed its CRISPR Therapeutics stake by 5.3% in Q1, selling 104,236 shares and retaining a position worth $88.19 million.
📈 GSK plc acquired a new position in CRISPR Therapeutics in Q4 valued at approximately $168.89 million.
📈 Orbis Allan Gray Ltd raised its stake by 76.9% in Q2, now owning 2.76 million shares valued at $134.47 million.
📈 State Street Corp increased its holdings by 35.6% in Q2 to own 3.27 million shares worth $159.08 million.
📈 ARK Investment Management LLC grew its position by 7.5% in Q4, holding 10.52 million shares valued at $551.78 million.
🏦 Norges Bank purchased a new stake in CRISPR Therapeutics in Q4 valued at approximately $25.71 million.
👤 Insider Naimish Patel sold 3,786 shares for $210,577 to cover tax withholding obligations related to equity vesting.
💰 Company insiders collectively own 5.20% of CRISPR Therapeutics stock following the recent insider sale.
📊 The company reported a loss per share of $1.28 and revenue of $1.46 million for the quarter ending March 31st.
🧬 CRISPR Therapeutics focuses on developing gene-editing therapies using its CRISPR/Cas9 platform for serious diseases.
💉 Its lead program CTX001 is an ex vivo edited cell therapy designed to treat sickle cell disease and beta-thalassemia with Vertex Pharmaceuticals.
📈 The stock has a market capitalization of $4.53 billion and a price-to-earnings ratio of -7.55.
Bullish Signals
- Major institutions added or initiated positions in CRISPR Therapeutics.
- ARK increased stake 7.5% to 10.5M shares valued at $551.78M.
- State Street lifted holdings 35.6% to 3.27M shares worth $159.08M.
- Orbis Allan Gray raised stake 76.9% with 1.2M shares at $134.47M.
- GSK initiated new position worth approximately $168.89 million.
Risk Factors
- Insider sold 3,786 shares worth $210,577.
- Holding reduced by 16.36%.
Bullish Signals
- Major institutional investors including GSK plc, Orbis Allan Gray Ltd, State Street Corp, ARK Investment Management LLC, and Norges Bank have recently added to or initiated positions in CRISPR Therapeutics.
- ARK Investment Management LLC significantly increased its stake by 7.5% in the fourth quarter, now holding over 10.5 million shares valued at $551.78 million.
- State Street Corp lifted its holdings by 35.6% in the second quarter, increasing its position to 3.27 million shares worth $159.08 million.
- Orbis Allan Gray Ltd raised its stake by 76.9% in the second quarter, acquiring an additional 1.2 million shares valued at $134.47 million.
- GSK plc initiated a new position in CRISPR Therapeutics in the fourth quarter worth approximately $168.89 million.
Risk Factors
- Insider Naimish Patel sold 3,786 shares for a total value of $210,577 to cover tax withholding obligations, reducing his personal holding by 16.36%.
Shares of CRISPR Therapeutics (CRSP) have struggled significantly, dropping nearly 8% year-to-date and over 80% from their 2021 highs. The gene-editing company faces valuation challenges due to steep losses and a lack of recent major updates on its existing product pipeline. Compounding these issues is the recent resignation of Chief Operating Officer Julianne Bruno, an event that has raised concerns among investors regarding internal stability and leadership continuity.
The stock currently exhibits high short interest, with over 20 million shares sold short representing approximately 25% of the public float. This heavy bearish positioning suggests that short-sellers are betting against the company's near-term prospects ahead of its upcoming earnings report scheduled for May 14, 2025. Analysts note that while the company has topped earnings estimates for three consecutive quarters, the high short interest creates a potential environment for significant volatility if results diverge from low expectations.
Despite the bearish sentiment, prominent investor Cathie Wood of Ark Invest maintains a bullish long-term view on gene editing technology. Although she recently trimmed her position by selling over $354,000 worth of shares, she still considers CRSP a potential performer that could outperform during an economic recession. The article highlights the company's strong balance sheet and its co-developed gene therapy, Casgevy (with Vertex Pharmaceuticals), as key assets that could drive a turnaround despite a lackluster rollout so far.
The stock currently trades at a low price-to-book ratio of 1.69x, which some analysts view as indicative of a deep-value opportunity rather than a high-growth stock. With low analyst expectations and a valuation that appears discounted relative to its potential, the article suggests that CRSP could be a dangerous name to short given its cash reserves and innovative pipeline. The upcoming earnings report is expected to be a critical catalyst that could trigger a significant price movement for the gene-editing innovator.
📉 Shares down 80% from 2021 highs and 8% year-to-date.
👤 Lost COO Julianne Bruno, raising leadership stability concerns.
🐻 Short interest exceeds 25% of the public float.
🏆 Beat earnings estimates for three consecutive quarters.
💰 Strong cash balance supports development despite losses.
📉 Shares of CRISPR Therapeutics (CRSP) are down nearly 8% year-to-date and over 80% from their 2021 all-time highs.
👤 The company recently lost its COO, Julianne Bruno, raising concerns about leadership stability among investors.
🐻 Short interest is high at over 20 million shares, representing approximately 25% of the public float.
📅 Upcoming quarterly earnings are scheduled for May 14, 2025, expected to cause significant market volatility.
🏆 CRSP has topped earnings estimates for three consecutive quarters despite a difficult stock trajectory.
💰 The company possesses a strong balance sheet with sufficient cash to absorb further losses during development.
💊 Casgevy, a gene therapy developed alongside Vertex Pharmaceuticals (VRTX), shows promise despite a slow rollout.
📉 Cathie Wood recently trimmed her position by selling over $354,000 worth of shares but remains bullish long-term.
📊 The stock trades at a low price-to-book ratio of 1.69x, suggesting potential deep-value characteristics.
🌧️ Ark Invest CEO Cathie Wood views CRSP as a name that could rise stronger than others during an economic recession.
Bullish Signals
- Topped earnings estimates for three straight quarters.
- Strong balance sheet with ample cash on hand.
- Trades at low price-to-book ratio of 1.69x.
- Potential outperformer during economic recession per Cathie Wood.
- Casgevy shows significant promise in clinical trials.
Risk Factors
- Shares down 8% YTD and 80% from 2021 highs.
- COO Julianne Bruno resigned, raising stability concerns.
- Short interest exceeds 25% of public float.
- Steep losses with no needle-moving product updates.
Bullish Signals
- The company has topped earnings estimates for three straight quarters, demonstrating consistent operational performance despite market headwinds.
- CRISPR Therapeutics maintains a strong balance sheet with ample cash on hand to absorb losses and fund future development.
- The stock trades at a low price-to-book ratio of 1.69x, which some analysts interpret as a deep-value opportunity rather than a growth failure.
- Cathie Wood highlights CRSP as a potential outperformer that could rise stronger than peers during an economic recession.
- Casgevy has demonstrated significant promise in clinical trials, offering a potential revenue driver once the rollout accelerates.
Risk Factors
- Shares are down nearly 8% year-to-date and more than 80% from their 2021 all-time highs, indicating severe investor skepticism.
- The untimely resignation of COO Julianne Bruno has raised red flags regarding internal stability and management continuity.
- High short interest of over 25% of the public float suggests a dominant bearish sentiment that could pressure the stock price.
- The company is characterized by steep losses and a lack of needle-moving updates on existing products, making valuation difficult.
Shares of CRISPR Therapeutics (CRSP) have struggled significantly, dropping nearly 8% year-to-date and over 80% from their 2021 highs. The gene-editing company faces valuation challenges due to steep losses and a lack of recent major updates on its existing product pipeline. Compounding these issues is the recent resignation of Chief Operating Officer Julianne Bruno, an event that has raised concerns among investors regarding internal stability and leadership continuity.
The stock currently exhibits high short interest, with over 20 million shares sold short representing approximately 25% of the public float. This heavy bearish positioning suggests that short-sellers are betting against the company's near-term prospects ahead of its upcoming earnings report scheduled for May 14, 2025. Analysts note that while the company has topped earnings estimates for three consecutive quarters, the high short interest creates a potential environment for significant volatility if results diverge from low expectations.
Despite the negative sentiment, prominent investor Cathie Wood maintains a bullish long-term view on gene editing technology. Although she recently trimmed her position by selling over $354,000 worth of shares, she still considers CRSP a potential performer that could outperform during an economic recession. The article highlights the company's strong balance sheet and its co-developed therapy, Casgevy (with Vertex Pharmaceuticals), as key assets that could drive a turnaround despite a lackluster rollout so far.
Valuation metrics suggest the stock may be undervalued relative to its growth potential, trading at 1.69 times price-to-book. With low analyst expectations and a deep-value profile, some observers view the current price of less than $39 per share as an opportunity rather than a risk. The consensus is that while the trajectory has been difficult, the combination of innovation, cash reserves, and potential for a short squeeze makes the stock dangerous to short.
📉 Shares down 80% from 2021 highs and 8% year-to-date.
👤 COO Julianne Bruno resigned earlier this month.
🐻 Short interest exceeds 20 million shares (25% float).
💰 Cathie Wood sold $354k but remains a believer.
💊 Casgevy therapy shows promise despite slow rollout.
📉 CRISPR Therapeutics shares are down nearly 8% year-to-date and over 80% from their 2021 all-time highs.
👤 Chief Operating Officer Julianne Bruno resigned earlier in the month, raising red flags for investors.
🐻 Short interest is high at over 20 million shares, representing roughly 25% of the public float.
📅 The company is set to report quarterly earnings on May 14, 2025, which could trigger volatility.
📈 CRISPR has topped earnings estimates for three consecutive quarters despite low market enthusiasm.
💰 Cathie Wood recently sold over $354,000 worth of shares but remains a long-term believer in the technology.
💊 Casgevy, a gene therapy developed with Vertex Pharmaceuticals, shows promise despite a slow rollout.
🛡️ The company maintains a strong balance sheet with sufficient cash to absorb further losses.
📊 CRSP trades at 1.69 times price-to-book, suggesting a deep-value profile relative to growth peers.
💹 Shares are currently trading at less than $39 per share according to the article's analysis.
Bullish Signals
- Topped earnings estimates for three straight quarters.
- Strong balance sheet with ample cash on hand.
- Casgevy gene therapy shows significant clinical promise.
- Investor Cathie Wood sees recession-resistant potential.
- Trades at 1.69 times price-to-book as deep-value.
- Low analyst expectations could trigger relief rally.
Risk Factors
- Shares down 8% YTD and over 80% from 2021 highs.
- COO resignation creates uncertainty about executive stability.
- Lack of product updates makes valuation difficult for investors.
- Short interest exceeds 25% of float, indicating bear dominance.
- Casgevy rollout lacksluster despite high market entry hopes.
Bullish Signals
- The company has topped earnings estimates for three straight quarters, demonstrating consistent operational performance despite market headwinds.
- CRISPR possesses a strong balance sheet with ample cash on hand to absorb losses and fund future development.
- Casgevy, the co-developed gene therapy, has demonstrated significant promise in its clinical trajectory.
- Prominent investor Cathie Wood views the company as a potential recession-resistant name capable of rising in a weaker economic environment.
- The stock trades at 1.69 times price-to-book, which is indicative of a deep-value stock rather than one requiring explosive growth metrics.
- With low expectations set by analysts, even modest positive results could lead to a significant relief rally for the share price.
Risk Factors
- Shares are down close to 8% year-to-date and more than 80% from their 2021 all-time highs, indicating severe investor skepticism.
- The untimely resignation of COO Julianne Bruno has introduced uncertainty regarding executive stability and operational leadership.
- There is a lack of needle-moving good updates on existing products, making the company difficult to value for traditional investors.
- High short interest of over 25% of the float suggests that bears dominate the stock and could continue to exert downward pressure.
- The rollout of Casgevy has been described as rather lackluster, failing to meet the high hopes surrounding its market entry.
Citizens Jmp reaffirmed its market outperform rating on CRISPR Therapeutics (CRSP) with a $80 price target, joining a chorus of recent analyst activity including Truist Financial's strong-buy upgrade and Piper Sandler raising its target to $110. While some analysts like Sanford C. Bernstein maintained hold ratings, the aggregate sentiment remains moderately bullish with an average target price of $67.78.
The company recently reported Q1 earnings of $1.46 million in revenue against a loss of $1.28 per share, resulting in negative net margins and return on equity. Analysts currently forecast a full-year loss of $4.89 per share for the current fiscal year, reflecting the high-burn nature of its gene-editing R&D pipeline focused on ex vivo therapies.
Institutional ownership remains robust at 69.20%, with significant recent accumulation from major funds including ARK Investment Management LLC, State Street Corp, and GSK plc. Notably, insider Naimish Patel sold shares totaling $210,577 to cover tax withholding obligations related to equity vesting, a transaction that reduced his direct ownership by 16.36%.
📈 Citizens Jmp restated rating to market outperform with $80 target.
📊 Truist upgraded to strong-buy; Piper Sandler raised target to $110.
💰 Q1 revenue hit $1.46M despite $1.28 loss per share.
🔮 Analysts forecast full-year earnings of -$4.89 per share.
🏦 ARK Management increased stake by 7.5% to over $551M.
📈 Citizens Jmp restated its rating to market outperform with an $80 price target on CRSP.
📊 Truist Financial upgraded the stock to strong-buy while Piper Sandler raised its target to $110.
💰 Q1 revenue reached $1.46 million, though the company posted a loss of $1.28 per share.
🔮 Analysts predict full-year earnings of -$4.89 per share for the current fiscal year.
🏦 ARK Investment Management LLC increased its stake by 7.5% to own over $551 million in shares.
📉 Insider Naimish Patel sold 3,786 shares worth $210,577 to cover tax withholding obligations.
🧬 The company focuses on ex vivo gene-editing therapies for sickle cell disease and thalassemia.
🤝 CRISPR Therapeutics collaborates with Vertex Pharmaceuticals on its lead CTX001 program.
📊 Institutional ownership stands at 69.20% following recent additions by State Street and GSK.
Bullish Signals
- Citizens Jmp reaffirmed market outperform rating with $80 price target.
- Truist upgraded to strong-buy; Piper Sandler raised target to $110.
- ARK added over $735 million in value to position.
- Strong pipeline targets sickle cell disease and beta-thalassemia.
Risk Factors
- Analysts forecast full-year loss of $4.89 per share.
- Insider sold 3,786 shares worth $210,577 for taxes.
Bullish Signals
- Citizens Jmp reaffirmed a market outperform rating with an $80 price target, signaling continued institutional confidence in the company's long-term prospects.
- Truist Financial upgraded CRSP to a strong-buy rating, while Piper Sandler raised its price target from $105 to $110, indicating growing analyst optimism.
- Major institutional investors including ARK Investment Management LLC, State Street Corp, and GSK plc have recently increased their positions, with ARK adding over $735 million in value.
- The company maintains a strong pipeline of ex vivo gene-editing therapies targeting serious diseases like sickle cell disease and transfusion-dependent beta-thalassemia.
Risk Factors
- Analysts forecast a full-year loss of $4.89 per share for the current fiscal year, highlighting the company's continued cash burn before commercialization milestones.
- Insider Naimish Patel sold 3,786 shares worth $210,577 to cover tax withholding obligations, reducing his direct ownership by 16.36%.
CRISPR Therapeutics (NASDAQ:CRSP) received a mixed analyst outlook following a downgrade by Wall Street Zen to a 'sell' rating, which contrasts with recent upgrades from Piper Sandler and Truist Financial. The company maintains a consensus 'Moderate Buy' rating with an average price target of $67.78, though individual targets vary significantly among major institutions like Morgan Stanley and Citigroup.
Financially, the biopharmaceutical firm reported Q1 earnings of $1.28 per share on revenue of $1.46 million. The company continues to operate with negative net margins and a negative return on equity, while analysts forecast a loss of $4.89 per share for the current year.
Institutional ownership remains robust at 69.20%, with significant additions from GSK plc, Orbis Allan Gray Ltd, State Street Corp, ARK Investment Management LLC, and Norges Bank in recent quarters. However, insider Naimish Patel sold approximately $210,577 worth of shares to cover tax withholding obligations related to equity vesting.
📉 Wall Street Zen downgraded CRISPR Therapeutics from 'hold' to 'sell'.
📈 Piper Sandler raised price target to $110 and Truist upgraded to 'strong-buy'.
💰 Q1 earnings hit $1.28 per share on $1.46 million revenue.
🏢 Institutional ownership is 69.20% with ARK and GSK increasing stakes.
👤 Insider Naimish Patel sold 3,786 shares for tax obligations.
📉 Wall Street Zen downgraded CRISPR Therapeutics from 'hold' to 'sell', creating a divergence in analyst sentiment.
📈 Piper Sandler raised its price target to $110.00 and Truist Financial upgraded the stock to 'strong-buy'.
💰 The company reported Q1 earnings of $1.28 per share on revenue of $1.46 million.
📉 Analysts forecast a loss of $4.89 per share for the current fiscal year.
🏢 Institutional ownership stands at 69.20% with major funds like ARK Investment Management and GSK increasing stakes.
👤 Insider Naimish Patel sold 3,786 shares worth $210,577 to cover tax withholding obligations.
Bullish Signals
- Major institutions like GSK and State Street increased holdings.
- Piper Sandler set $110.00 price target with overweight rating.
- Truist Financial upgraded stock to strong-buy rating.
- MarketBeat consensus Moderate Buy with $67.78 average target.
Risk Factors
- Wall Street Zen downgraded stock to 'sell' rating.
- Negative net margins of -13,856.54% and ROE of -25.66%.
- Analysts forecast $4.89 loss per share for current year.
Bullish Signals
- Major institutional investors including GSK plc, Orbis Allan Gray Ltd, State Street Corp, ARK Investment Management LLC, and Norges Bank have recently added new positions or increased holdings in the stock.
- Piper Sandler restated an 'overweight' rating with a price target of $110.00, while Truist Financial upgraded the stock to a 'strong-buy' rating.
- The company maintains a consensus 'Moderate Buy' rating from MarketBeat with an average analyst price target of $67.78.
Risk Factors
- Wall Street Zen downgraded the stock from a 'hold' to a 'sell' rating, indicating bearish sentiment from at least one major analyst.
- The company reported negative net margins of -13,856.54% and a negative return on equity of -25.66% for the quarter.
- Analysts forecast a loss of $4.89 per share for the current year, suggesting continued financial losses in the near term.
Crispr Therapeutics (CRSP) received FDA pediatric approval for Casgevy, a gene-editing therapy for sickle cell disease and beta-thalassemia. This regulatory milestone expands the company's addressable market and reinforces its leadership in CRISPR/Cas9 technology, despite previous challenges with complex treatment logistics and high costs associated with the therapy.
Following the announcement, CRSP stock surged over 8% to reach a four-month high of $60 per share, pushing the market capitalization to approximately $5.79 billion. The approval is viewed as a significant catalyst for accelerated revenue growth, driven by an expanded patient pool and technical advancements that could drive the stock price toward historic highs.
Beyond Casgevy, CRSP's pipeline includes innovative in-vivo and allogeneic programs targeting cardiovascular and autoimmune diseases. These initiatives aim to simplify gene therapy applications and further expand the company's therapeutic reach, positioning it for continued strategic growth in the gene editing sector.
🏥 FDA pediatric approval expands Casgevy market for sickle cell and beta-thalassemia.
📈 Stock surged 8% to $60/share on regulatory win.
💰 Market cap hit $5.79 billion reflecting investor optimism.
🔬 Robust pipeline includes cardiovascular and autoimmune disease programs.
⚠️ High costs and complex protocols hinder commercial uptake.
🏥 CRISPR Therapeutics secured FDA pediatric approval for Casgevy, expanding its market potential for sickle cell disease and beta-thalassemia treatments.
📈 Stock price jumped over 8% to a four-month high of $60 per share following the regulatory win.
💰 Market capitalization reached $5.79 billion as investors reacted positively to the expanded addressable market.
🔬 The company maintains a robust pipeline including in-vivo and allogeneic programs for cardiovascular and autoimmune diseases.
⚠️ Commercial uptake remains challenging due to complex treatment protocols and high therapy costs.
🚀 Pediatric approval is expected to drive significant upside potential toward historic share price levels.
Bullish Signals
- FDA pediatric approval expands addressable market.
- Stock surged 8% to $60 four-month high.
- Market cap reached $5.79 billion.
- Revenue growth expectations accelerate.
Risk Factors
- High costs and complex logistics slow Casgevy uptake.
- Revenue relies heavily on Casgevy amid pipeline risks.
Bullish Signals
- CRISPR Therapeutics received FDA pediatric approval for Casgevy, significantly expanding its addressable market and reinforcing its leadership in CRISPR/Cas9 gene editing technology.
- The stock surged over 8% to a four-month high of $60 per share, reflecting strong investor confidence in the company's commercial prospects following the regulatory milestone.
- Market capitalization increased to $5.79 billion, validating the market's view that Casgevy's multibillion-dollar potential is being realized despite initial commercial hurdles.
- The approval accelerates revenue growth expectations as the patient pool expands and technical advances simplify gene therapy applications for a broader demographic.
Risk Factors
- Casgevy faces continued commercial headwinds due to complex treatment logistics and high costs, which have historically slowed initial uptake despite strong clinical efficacy.
- The company's reliance on Casgevy as a primary revenue driver remains a concentration risk if broader pipeline programs in cardiovascular or autoimmune diseases face development delays.
Analysts have recently upgraded their consensus revenue and earnings-per-share (EPS) forecasts for CRISPR Therapeutics (CRSP), projecting year-over-year EPS growth ahead of the company's upcoming earnings report. This shift in expectations highlights growing confidence in the near-term revenue potential of gene-editing therapies, particularly those derived from the strategic partnership with Vertex Pharmaceuticals.
The article notes that while this optimism may sharpen focus on commercialization milestones and early revenue traction, significant risks remain. CRISPR Therapeutics continues to operate with a very small current revenue base of approximately US$4.10 million and faces substantial ongoing losses. The company's history of frequent equity raises keeps concerns about share dilution and future funding needs front and center for investors.
Despite these challenges, the stock has recently gained against a softer market, suggesting it may be undervalued relative to its long-term potential. Fair value estimates from the Simply Wall St community vary widely, ranging from US$68 to US$176 per share, reflecting divergent views on whether the company can successfully transition from promising science to a sustainable business model.
📈 Analysts raised revenue and EPS forecasts ahead of earnings.
💰 Company reports $4.1M revenue with significant operating losses.
🤝 Optimism driven by Vertex Pharmaceuticals partnership potential.
⚠️ Risks include share dilution from frequent equity raises.
🎯 Fair value estimates range from $68 to $176 per share.
📈 Analysts have raised consensus revenue and EPS forecasts for CRISPR Therapeutics ahead of its upcoming earnings report.
💰 The company currently reports a very small revenue base of approximately US$4.10 million while operating with sizeable losses.
🤝 Heightened optimism is specifically tied to the commercialization potential of the Vertex Pharmaceuticals partnership.
⚠️ Frequent equity raises and ongoing unprofitability keep risks regarding share dilution and funding needs prominent.
📉 Recent stock price gains against a softer market suggest investors may view the current valuation as potentially undervalued.
🎯 Fair value estimates from analysts vary significantly, ranging from US$68 to US$176 per share.
Bullish Signals
- Analysts upgraded revenue and EPS forecasts.
- Shares appreciated despite softer market.
- Vertex partnership drives commercialization.
Risk Factors
- Substantial losses with only US$4.10 million revenue.
- Frequent equity raises risk share dilution.
- Critical funding needed for business transition.
Bullish Signals
- Analysts have upgraded revenue and EPS forecasts, indicating growing confidence in near-term gene-editing revenue potential.
- The company's shares have recently appreciated against a softer broader market, suggesting positive investor sentiment.
- Strategic partnership with Vertex Pharmaceuticals is viewed as a key driver for upcoming commercialization milestones.
Risk Factors
- CRISPR Therapeutics continues to report substantial losses and maintains a very small revenue base of US$4.10 million.
- The company has a history of frequent equity raises, creating ongoing risks related to share dilution for existing shareholders.
- Significant funding needs remain a critical challenge as the company attempts to transition from science to a sustainable business.
CRISPR Therapeutics (NASDAQ:CRSP) saw its analyst rating upgraded to 'Hold' by Wall Street Zen, following a recent wave of mixed-to-positive sentiment from major institutions. Citigroup restated its rating to 'market outperform,' while Sanford C. Bernstein raised its price target to $56.00 and Evercore set an objective at $76.00. Conversely, Morgan Stanley maintained an 'equal weight' rating with a $60.00 target. The consensus average rating remains 'Moderate Buy' with a target price of $67.78, reflecting a generally positive but cautious outlook from the sell-side.
The company reported Q1 earnings on March 31st, posting a loss of $1.28 per share against minimal revenue of $1.46 million. Financial metrics showed a negative return on equity of -25.66% and a significant net margin contraction of -13,856.54%. Analysts currently anticipate the company will report an average annual loss of $4.89 per share for the current fiscal year, highlighting its continued pre-revenue or early-stage profitability challenges despite its technological advancements.
Institutional ownership remains robust at 69.20%, with notable increases in stakes from GSK plc, Orbis Allan Gray Ltd, State Street Corp, and ARK Investment Management LLC during the second and fourth quarters. However, insider Naimish Patel sold 3,786 shares worth approximately $210,577 to cover tax withholding obligations related to equity vesting, reducing his direct ownership by 16.36%. The company focuses on gene-editing therapies using its CRISPR/Cas9 platform, with lead program CTX001 targeting sickle cell disease and beta-thalassemia in collaboration with Vertex Pharmaceuticals.
📈 Wall Street Zen upgraded CRISPR Therapeutics to 'Hold'.
💰 Q1 loss hit $1.28/share on just $1.46M revenue.
🏦 Institutional ownership reached 69.20% with major additions.
🧬 Lead program CTX001 targets sickle cell disease.
🔬 Uses proprietary CRISPR/Cas9 gene-editing technology.
📈 Wall Street Zen upgraded CRISPR Therapeutics to a 'Hold' rating, joining recent positive actions from Citigroup and Evercore.
🎯 Analyst consensus maintains a 'Moderate Buy' status with an average price target of $67.78.
💰 Q1 earnings showed a loss of $1.28 per share on revenue of only $1.46 million.
📉 The company reported a negative net margin of -13,856.54% and negative return on equity of -25.66%.
🔮 Analysts forecast an average annual loss of $4.89 per share for the current fiscal year.
🏦 Institutional ownership stands at 69.20%, with significant additions from ARK Investment Management and State Street Corp.
📉 Insider Naimish Patel sold 3,786 shares worth $210,577 to cover tax withholding obligations.
🧬 Lead program CTX001 targets sickle cell disease and beta-thalassemia in collaboration with Vertex Pharmaceuticals.
🔬 The company utilizes proprietary CRISPR/Cas9 technology for ex vivo and in vivo gene-editing therapies.
Bullish Signals
- Wall Street Zen upgraded stock to Hold from Sell.
- Citigroup restated rating to market outperform.
- Sanford Bernstein raised price target to $56.00.
- Evercore issued outperform rating with $76.00 objective.
- Institutional investors increased holdings in recent quarters.
Risk Factors
- Q1 loss of $1.28 per share indicates ongoing profitability challenges.
- Minimal revenue of $1.46 million suggests limited commercial scale.
- Negative ROE of -25.66% and massive net margin contraction of -13,856.54%.
- Analysts expect continued losses with average EPS of -$4.89 for the year.
- Insider sold 3,786 shares worth $210,577, reducing ownership by 16.36%.
Bullish Signals
- Wall Street Zen upgraded the stock to a 'Hold' rating, signaling improved sentiment from a previous 'Sell' classification.
- Citigroup restated its rating to 'market outperform,' indicating confidence in the company's long-term prospects.
- Sanford C. Bernstein increased its price target to $56.00 and maintained a 'market perform' rating.
- Evercore issued an 'outperform' rating with a high price objective of $76.00.
- Major institutional investors including ARK Investment Management, State Street Corp, and GSK plc have increased their holdings in the second or fourth quarter.
- The stock maintains a consensus 'Moderate Buy' rating from MarketBeat with a target price of $67.78.
Risk Factors
- The company reported a significant loss of $1.28 per share for the first quarter, indicating ongoing profitability challenges.
- Revenue was minimal at only $1.46 million for the quarter, suggesting limited commercial scale at this stage.
- Financial metrics include a negative return on equity of -25.66% and a massive net margin contraction of -13,856.54%.
- Analysts anticipate continued losses with an average expected EPS of -$4.89 for the current fiscal year.
- Insider Naimish Patel sold 3,786 shares worth $210,577 to cover tax obligations, representing a 16.36% reduction in his direct ownership.
Simply Wall St analysis suggests CRISPR Therapeutics (CRSP) shares are trading at US$54.09, representing a significant discount to its estimated fair value of US$177.40 based on a discounted cash flow (DCF) model projecting future cash flows.
The stock has demonstrated solid short-term momentum with a 7-day return of 8.61% and a 30-day return of 8.40%, contributing to a one-year total shareholder return of 22.24%. However, the company currently reports ongoing losses of US$568.534 million and relies on the successful development of its early-stage pipeline.
While the DCF model indicates the stock is undervalued by approximately 69.5%, analyst price targets present a more cautious outlook, with an average target of US$83.52 implying only a 54% discount to current prices. The article highlights the divergence between high-growth cash flow expectations and near-term profitability concerns typical for clinical-stage biotech firms.
Investors are presented with a choice between trusting the higher DCF valuation driven by future revenue growth potential or the more conservative analyst consensus. The analysis notes that while the company focuses on gene editing medicines using its CRISPR/Cas9 platform, assumptions regarding trial data and regulatory milestones could quickly alter these underlying valuations.
📊 CRSP trades at $54, a 69.5% discount to $177 fair value.
📈 Stock gained 8.61% last week and 8.40% last month.
💰 Company reports $568.5M losses against only $4.1M revenue.
🔬 Valuation depends on future cash flows, not current profits.
⚠️ Success hinges on pipeline development and upcoming trial data.
📊 CRISPR Therapeutics (CRSP) is trading at US$54.09, which Simply Wall St's DCF model values as a 69.5% discount to a fair value of US$177.40.
📈 The stock has posted strong short-term performance with an 8.61% return over the last week and an 8.40% return over the last month.
💰 The company currently reports ongoing losses totaling US$568.534 million while generating revenue of US$4.1 million.
🔬 As a clinical-stage biotech, CRSP's valuation relies heavily on future cash flow projections rather than current net income or profitability.
📉 Analyst price targets are more conservative than the DCF model, with an average target of US$83.52 representing only a 54% discount to the current price.
⚠️ The valuation assumes successful development of the early-stage pipeline and favorable outcomes from upcoming trial data and regulatory milestones.
Bullish Signals
- 8.61% gain over past week and 8.40% over month.
Risk Factors
- Substantial ongoing losses of US$568.534 million.
- Low current revenue at only US$4.1 million.
- Cautious analyst targets average US$83.52.
- High valuation relies on early-stage pipeline success.
Bullish Signals
- The stock exhibits strong short-term momentum with an 8.61% gain over the past week and an 8.40% gain over the past month.
- Simply Wall St's discounted cash flow model estimates a fair value of US$177.40, implying the current price is significantly undervalued at a 69.5% discount.
- The company has achieved a positive one-year total shareholder return of 22.24% despite being in a clinical-stage development phase.
Risk Factors
- CRISPR Therapeutics reports substantial ongoing losses of US$568.534 million, indicating it is not yet profitable.
- The company's current revenue is low at US$4.1 million, reflecting its early-stage commercial operations.
- Analyst price targets are more cautious than the DCF model, with an average target of US$83.52 suggesting less optimism about immediate value realization.
- The high valuation depends entirely on the successful development of an early-stage pipeline and favorable regulatory outcomes.
CRISPR Therapeutics (NASDAQ: CRSP) shares have recently declined, trading around $49.37 after dropping 5% in the past week and 8% year-to-date. Despite this short-term weakness, investment firm Piper Sandler has raised its price target to $110, implying over 120% upside potential from current levels. The analyst maintains an Overweight rating on the stock, citing a strengthened balance sheet and significant commercial momentum as key drivers for future growth.
The primary catalyst for the bullish outlook is a freshly issued $600 million convertible note due in March 2031, which provides the company with pro forma cash of $2.56 billion. This substantial liquidity extends CRISPR's runway to advance multiple pipeline programs through clinical development without the need for near-term capital raises, effectively de-risking the pre-profitability biotech. Additionally, its approved gene therapy, CASGEVY, generated $116 million in full-year 2025 revenue with patient initiations nearly tripling year-over-year.
Beyond commercial success, CRISPR is advancing a robust cardiovascular pipeline, specifically CTX310, which has shown strong early results published in the New England Journal of Medicine and is moving toward Phase 1b. The company also plans to expand CASGEVY's pediatric label for ages 5-11 with regulatory submissions expected in the first half of 2026. With deep cash reserves, CRISPR can simultaneously advance programs like CTX340 for hypertension and zugo-cel for autoimmune diseases without dilutive equity raises.
Reaching the $110 target requires sustained acceleration in CASGEVY patient volumes, FDA approval of the pediatric label expansion, and successful readouts from cardiovascular or autoimmune pipeline candidates. While CRISPR continues to generate significant operating losses with no near-term path to profitability, making execution on every milestone non-negotiable, Piper Sandler views the $110 target as a credible long-term value case for investors willing to accept biotech-level volatility.
📈 Piper Sandler raises price target to $110, implying over 120% upside.
💰 Issued $600M convertible note for $2.56B pro forma cash and extended runway.
📊 CASGEVY generated $116M revenue in 2025 with patient initiations nearly tripling.
👶 Pediatric label expansion for CASGEVY expected by FDA in H1 2026.
⚠️ Significant operating losses remain primary risk requiring flawless execution for profitability.
📈 Piper Sandler raises CRISPR Therapeutics price target to $110 from current levels of ~$49.37, implying over 120% upside.
💰 Company issued a $600M convertible note due March 2031, resulting in $2.56B pro forma cash and extended runway.
📊 Approved gene therapy CASGEVY generated $116M revenue in 2025 with patient initiations nearly tripling year-over-year.
👶 Pediatric label expansion for CASGEVY (ages 5-11) is under submission with FDA approval expected in H1 2026.
❤️ Cardiovascular program CTX310 advanced to Phase 1b following strong early data published in the New England Journal of Medicine.
🧬 Pipeline includes CTX340 for refractory hypertension, zugo-cel for autoimmune diseases, and CTX611 advancing simultaneously.
📉 Stock is down 8% year-to-date but maintains 79% institutional ownership with an Overweight rating from Piper Sandler.
⚠️ Primary risk remains significant operating losses with no near-term path to profitability requiring flawless execution.
Bullish Signals
- Piper Sandler raised price target to $110.
- $2.56B cash eliminates need for dilutive equity raises.
- CASGEVY generated $116M revenue with 30 Q4 infusions.
- Pediatric label expansion expected in H1 2026.
- CTX310 advances to Phase 1b after NEJM results.
Risk Factors
- Significant operating losses with no near-term profitability path.
Bullish Signals
- Piper Sandler raised the price target to $110, signaling strong institutional confidence in the company's long-term value proposition despite recent share price declines.
- The issuance of a $600 million convertible note has secured $2.56 billion in pro forma cash, eliminating the immediate need for dilutive equity raises and allowing focus on clinical development.
- CASGEVY demonstrated robust commercial momentum with $116 million in 2025 revenue and patient initiations nearly tripling year-over-year to 30 infusions in Q4 alone.
- The upcoming pediatric label expansion for CASGEVY covering ages 5-11 is expected in H1 2026, which could meaningfully expand the addressable market for the approved therapy.
- CTX310 has demonstrated strong early results in cardiovascular disease published in the New England Journal of Medicine, advancing to Phase 1b and potentially reframing the company's long-term revenue profile.
- Deep cash reserves enable CRISPR to advance multiple high-value programs like CTX340, zugo-cel, and CTX611 simultaneously without financial constraints or dilution.
Risk Factors
- CRISPR Therapeutics continues to generate significant operating losses with no near-term path to profitability, making execution on every pipeline milestone non-negotiable.
- Reaching the $110 target requires sustained acceleration in CASGEVY patient volumes and successful FDA approval of the pediatric label expansion.
- The stock has recently dropped 5% over the past week and is down 8% year-to-date, reflecting ongoing market volatility typical for pre-profitability biotech companies.
CRISPR Therapeutics (NASDAQ: CRSP) stock has experienced significant volatility as the market evaluates its transition from a clinical-stage biotech to a commercial entity. While the company achieved a major milestone in late 2023 with the regulatory approval of CASGEVY, the first CRISPR-based treatment for sickle cell disease, revenue generation remains slow. In the first quarter of 2026, the company reported only $1.46 million in revenue against a net loss of $122.9 million, highlighting the gap between scientific breakthroughs and commercial profitability.
The article notes that commercial adoption for gene-editing therapies is gradual due to complex treatment procedures and specialized center requirements. Despite this slow uptake, CRISPR maintains a strong balance sheet with approximately $2.4 billion in cash and marketable securities as of the first quarter, providing management with flexibility to fund research without immediate capital raises. The company is also developing CTX112, an investigational off-the-shelf CAR-T therapy for cancer designed to lower manufacturing costs and scale production compared to traditional patient-specific treatments.
Analysts view the stock's volatility as a reflection of uncertainty regarding future patient volumes and the timeline for CASGEVY to become commercially meaningful. While the potential CAR-T market is projected to grow from $5.8 billion in 2025 to over $22 billion by 2033, capturing even a small percentage could yield significant revenue. The investment thesis hinges on successful execution of pipeline programs and the ability to scale patient volumes while managing ongoing losses.
✅ CASGEY approved late 2023 as first CRISPR sickle cell cure.
💰 Q1 2026 revenue $1.46M, net loss $122.9M, cash $2.4B.
🔬 CTX112 off-the-shelf CAR-T cancer therapy derived from healthy donor cells.
📈 Global CAR-T market valued $5.8B in 2025, projected $22B by 2033.
⏳ Commercial adoption slow due to complex procedures and specialized center needs.
📉 CRISPR Therapeutics stock has been volatile as investors assess its transition from clinical-stage to commercial biotech status.
✅ CASGEVY received regulatory approval in late 2023 as the first CRISPR-based treatment for sickle cell disease.
💰 The company reported $1.46 million in revenue and a $122.9 million net loss in Q1 2026.
🏦 CRISPR holds approximately $2.4 billion in cash, cash equivalents, and marketable securities as of Q1 2026.
🔬 CTX112 is an investigational off-the-shelf CAR-T therapy for cancer derived from healthy donor cells.
📈 The global CAR-T market was valued at $5.8 billion in 2025 and could reach over $22 billion by 2033.
⏳ Commercial adoption is described as slow due to complex treatment procedures and specialized center requirements.
🚀 Off-the-shelf manufacturing for CTX112 aims to lower costs and shorten treatment timelines compared to traditional CAR-T.
📊 The market is currently pricing in uncertainty regarding future patient volumes and commercial scaling timelines.
Bullish Signals
- Robust balance sheet with $2.4 billion cash.
- CASGEY approved for sickle cell disease.
- CTX112 is scalable off-the-shelf CAR-T therapy.
- CAR-T market grows from $5.8B to $22B.
- 5% market share implies >$1B annual revenue.
Risk Factors
- Net loss of $122.9 million in Q1 2026.
- Revenue remains low at just $1.46 million.
- Gradual commercial adoption due to complex procedures.
- Risks from drug development and uncertain adoption.
Bullish Signals
- CRISPR Therapeutics holds a robust balance sheet with approximately $2.4 billion in cash, cash equivalents, and marketable securities as of the first quarter.
- The company has successfully developed CASGEVY, which received regulatory approval in late 2023 for treating sickle cell disease.
- CTX112 is an investigational off-the-shelf CAR-T therapy designed to be produced at scale from healthy donor cells, potentially lowering manufacturing costs.
- The potential global CAR-T market is projected to grow significantly from $5.8 billion in 2025 to over $22 billion by 2033.
- Capturing just 5% of the future CAR-T market could imply more than $1 billion in annual revenue potential for the company.
Risk Factors
- CRISPR Therapeutics reported a significant net loss of $122.9 million in the first quarter of 2026.
- Revenue remains low at just $1.46 million in Q1 2026, indicating a slow transition from scientific breakthrough to commercial revenue generation.
- Commercial adoption of gene-editing therapies is described as gradual due to complex preparation procedures and lengthy approval processes.
- The company faces inherent risks associated with drug development and uncertain commercial adoption rates for its pipeline programs.
Metagenomi Therapeutics, Inc. (NASDAQ: MGX), an in vivo genome editing company headquartered in Emeryville, California, reported its first quarter 2026 financial results and key business milestones on May 11, 2026. The company maintains a substantial cash position with $140.2 million in cash, cash equivalents, and available-for-sale marketable securities as of March 31, 2026, providing sufficient runway to support operations through the fourth quarter of 2027. This liquidity enables Metagenomi to continue advancing its clinical programs without immediate pressure for external financing.
The primary strategic focus remains on MGX-001, a lead development program targeting hemophilia A, which is proceeding toward an Investigational New Drug (IND) submission expected in the fourth quarter of 2026. Following regulatory clearance, the company plans to initiate first-in-human clinical trials in 2027. To support this effort, the company recruited Kapil Saxena, MD, who previously held leadership roles at Autolus, Daiichi Sankyo, and Bayer, specifically to spearhead the clinical development of MGX-001.
Financially, Metagenomi recorded $19.3 million in Research and Development expenses for the quarter ended March 31, 2026, a decrease from $25.1 million in the comparable period of 2025. General and Administrative expenses were $6.5 million, also slightly down from $6.8 million in the prior year. Beyond MGX-001, the company highlighted a publication in Nature Structural & Molecular Biology describing MG119-28, a compact CRISPR nuclease that demonstrates superior genome editing efficiency. The company is also exploring additional indications for its site-specific genome integration system and has partnership assets targeting cardiometabolic diseases, all aimed at delivering one-time curative genetic medicines.
📅 Metagenomi reported Q1 2026 results with $140.2M cash reserves.
🧬 Lead asset MGX-001 targets IND submission by Q4 2026 for a curative hemophilia A treatment.
👩⚕️ Dr. Kapil Saxena joins to lead clinical development while R&D costs drop.
🚀 The company plans first-in-human trials in 2027 using its genome integration platform.
📅 Metagenomi Therapeutics announced its first quarter 2026 financial results and provided key business updates on May 11, 2026.
🧬 The company's lead program, MGX-001 for hemophilia A, is on track for a regulatory submission (IND) in the fourth quarter of 2026.
🎯 Pending regulatory clearance, the company plans to initiate first-in-human clinical trials for MGX-001 in 2027.
💼 Metagenomi reported $140.2 million in cash, cash equivalents, and marketable securities as of March 31, 2026.
🚀 Management expects current cash reserves to support operations through the fourth quarter of 2027.
📉 Research and development expenses decreased to $19.3 million for Q1 2026, down from $25.1 million in Q1 2025.
📜 General and administrative expenses totaled $6.5 million for the quarter, slightly lower than the $6.8 million spent in the same period last year.
👩⚕️ Dr. Kapil Saxena joined the company as a new executive to lead the clinical development of the MGX-001 program.
🔬 A recent publication in Nature Structural & Molecular Biology highlighted the potential of MG119-28, a compact CRISPR nuclease with enhanced editing efficiency.
💉 MGX-001 is designed as a one-time curative treatment to provide lifelong protection against bleeding events and joint damage for hemophilia A patients.
🧬 The company's MGX-001 Large Gene Integration System targets protein replacement via site-specific genome insertion following successful proof-of-concept in non-human primates.
🤝 Beyond the lead asset, Metagenomi is pursuing additional indications including cardiometabolic diseases using its proprietary site-specific genome integration technology.
🏢 The company is headquartered in Emeryville, California, and trades on the Nasdaq under the ticker symbol MGX.
⚠️ Management issued a cautionary note regarding forward-looking statements due to inherent uncertainties in product development and regulatory timelines.
Bullish Signals
- IND for MGX-001 submission expected Q4 2026.
- First-in-human studies targeted for 2027.
- Nature publication highlights superior MG119-28 nuclease performance.
- $140.2M cash provides runway through Q4 2027.
- R&D expenses decreased to $19.3M in Q1 2026.
- General and administrative expenses stable at $6.5M.
- Dr. Kapil Saxena joins with Autolus leadership experience.
- MGX-001 shows best-in-class profile for hemophilia A.
- Platform enables site-specific genome integration across diseases.
Risk Factors
- Cash reserves of $140.2M sustain liquidity only through Q4 2027.
- Liquidity pressure risk if clinical timelines slip or costs escalate.
- R&D expenses rose 23% QoQ to $19.3M in Q1 2026.
- Development costs are rising despite current absence of revenue.
Bullish Signals
- Metagenomi Therapeutics is on track to submit an Investigational New Drug (IND) application for its lead program MGX-001 in the fourth quarter of 2026, paving the way for first-in-human studies in 2027.
- A publication in Nature Structural & Molecular Biology highlights MG119-28, a proprietary compact CRISPR nuclease with enhanced genome editing efficiency and superior performance relative to previously identified nucleases.
- The company maintains a strong cash position of $140.2 million as of March 31, 2026, providing sufficient runway to support operations through the fourth quarter of 2027.
- Cost discipline is evident with R&D expenses decreasing to $19.3 million in Q1 2026 compared to $25.1 million in the same period last year.
- General and administrative expenses remained stable at $6.5 million, demonstrating controlled operational overhead.
- Dr. Kapil Saxena joined the company with extensive leadership experience from Autolus, Daiichi Sankyo, and Bayer to spearhead clinical development for MGX-001.
- MGX-001 has demonstrated a best-in-class preclinical profile with durable gene expression in NHPs, aiming to provide one-time curative treatments for hemophilia A.
- The company's technology platform enables site-specific genome integration, allowing for protein replacement via gene insertion across multiple disease indications.
Risk Factors
- Cash reserves of $140.2 million as of March 31, 2026 are sufficient only through the fourth quarter of 2027, creating potential liquidity pressure if clinical timelines slip or operational costs escalate beyond current projections.
- R&D expenses increased by approximately 23% quarter-over-quarter to $19.3 million in Q1 2026 compared to $25.1 million in the prior-year equivalent period for 2025, indicating rising development costs despite overall revenue generation remaining absent.
CRISPR Therapeutics AG, trading under the ticker CRSP, is currently identified as a trending stock on Zacks.com following increased search volume and market attention. The article analyzes the stock's recent performance, noting that shares rose 1.4% over the past month compared to an 11% gain for the S&P 500 composite and contrasting this with the biotechnology industry's 1% decline. While acknowledging that media rumors often drive short-term trends, the content emphasizes that fundamental factors and future earnings projections are more relevant for long-term investment decisions, specifically citing the Zacks methodology which links earnings estimate revisions to stock fair value.
The article provides specific financial estimates and actual performance data, highlighting that CRSP is expected to incur a loss of $1.11 per share for the current quarter, representing a 14% improvement from the year-ago quarter. Analyst consensus estimates show significant projected growth, with full-year earnings expected at -$5.07 (a 21.6% increase) and next fiscal year earnings projected at $4.35 (a 14.2% increase). Revenue projections are particularly steep, with current quarter sales estimated at $8.18 million, which represents an 818.8% year-over-year growth rate, compared to actual reported revenues of $1.46 million in the last quarter, a 67.8% increase that missed estimates by approximately 83%.
Valuation metrics are also scrutinized, with the company receiving a Zacks Value Style Score of F, indicating it trades at a significant premium relative to its peers. This premium is attributed to high price-to-earnings and other valuation multiples. Despite the high growth expectations in revenue and earnings revisions, the analysis concludes that the stock holds a Zacks Rank of 3 (Hold), suggesting that while fundamental trends are positive, the near-term price performance is likely to track with the broader market rather than experience an immediate outperformance.
📉 Recent shares underperformed, while last quarter's revenue significantly missed estimates.
📈 Losses narrowed by 14%, projecting a future profit turnaround to $4.35.
⚠️ High growth forecasts coexist with a premium valuation and "Hold" rating.
📈 CRISPR Therapeutics (CRSP) shares have gained 1.4% over the past month, significantly underperforming the S&P 500's 11% gain and lagging its own industry's -1% movement.
🧬 The company is expected to post a quarterly loss of $1.11 per share, representing a +14% improvement compared to the same quarter last year.
📉 Consensus earnings estimates for the current fiscal year stand at -$5.07, while the next year's projection shows a turnaround to $4.35.
💰 Revenue growth is projected to be explosive in the short term, with current quarter estimates pointing to an 818.8% increase year-over-year.
📊 Actual revenue reported for the last quarter was $1.46 million, which missed the consensus estimate by -82.62%.
🤖 The Zacks Rank tool has assigned CRSP a rating of #3 (Hold), suggesting the stock may perform in line with the broader market in the near term.
💸 The company carries an F-grade on the Zacks Value Style Score, indicating it is currently trading at a premium valuation relative to its peers.
🔄 Analyst estimates for the current quarter have increased by 5.9% over the last 30 days, while full-year earnings forecasts have dipped slightly.
⚠️ Historical performance shows the company beat EPS expectations twice in the last four quarters but failed to meet consensus revenue estimates during that same period.
📈 The forward 12-month consensus EPS estimate is projected to grow by +14.2% from the prior year's figures.
🔍 Zacks emphasizes that future stock performance is determined more by fundamental factors like earnings revisions than by short-term media trends or rumors.
🏆 Despite a positive shift in loss estimates, the current valuation multiples suggest the stock remains expensive compared to the biomedical and genetics industry peers.
Bullish Signals
- CRISPR Therapeutics revenue grew 67.8% YoY to $1.46 million.
- EPS improved from -$1.58 to -$1.28 year-over-year.
- Current quarter earnings estimates rose 14% to -$1.11.
- Full-year earnings projected to grow 21.6% YoY.
- Next fiscal year revenue forecast up 274.1%.
- Beats EPS and revenue estimates twice in last four quarters.
Risk Factors
- Stock underperformed S&P 500 by -9% while index gained +11%.
- Earnings estimates face downward pressure with -2.7% to -3.5% revisions.
- Zacks Rank #3 indicates expected in-line performance rather than outperformance.
- Valuation concerns exist with an 'F' grade on Value Style Score.
- Revenue missed consensus by -82.62% and EPS dropped $1.11/share.
- High valuation and quarterly losses create near-term performance risks.
Bullish Signals
- CRISPR Therapeutics reported revenues of $1.46 million in the last reported quarter, representing a year-over-year change of +67.8%.
- EPS of -$1.28 for the same period compares favorably to -$1.58 a year ago, indicating an improvement in profitability despite the loss.
- For the current quarter, earnings estimates are expected to be -$1.11 per share, which indicates a positive change of +14% from the year-ago quarter.
- The consensus earnings estimate for the current fiscal year shows a strong year-over-year growth projection of +21.6%.
- Revenue forecasts for the next fiscal year indicate a significant potential increase of +274.1% compared to current projections.
- Over the last four quarters, the company has surpassed consensus EPS estimates two times and topped revenue estimates multiple times during this period.
Risk Factors
- The stock has underperformed the broader market, losing $0.9% relative to the S&P 500 while the overall index gained +11% over the past month.
- Earnings estimates are facing downward pressure, with recent revisions showing a -2.7% decline for the next fiscal year and a -3.5% drop for the current fiscal year over the last 30 days.
- The company received a Zacks Rank #3 (Hold), indicating that it is expected to perform only in line with the broader market rather than outperforming.
- Valuation metrics are concerning, as CRSP has received an 'F' grade on its Value Style Score, suggesting it is trading at a premium to its peers.
- The most recent quarterly revenue of $1.46 million significantly missed the consensus estimate of $8.39 million by -82.62%, and EPS also missed estimates by -12.28%.
- Despite positive long-term growth projections, the high valuation and current lack of consistent profitability (loss of $1.11 per share this quarter) create risks for near-term performance.
CRISPR Therapeutics AG (CRSP) is described as a trending stock on Zacks.com, with shares having gained 1.4% over the past month compared to the S&P 500's 11% gain and contrasting with its medical genetics industry peers which lost 1%. The article focuses on fundamental factors driving buy-and-hold decisions rather than short-term rumors, emphasizing that fair value is determined by future earnings streams as assessed by sell-side analyst estimate revisions. For the current quarter, CRSP is projected to post a loss of $1.11 per share, representing a 14% improvement from the prior year, while consensus earnings estimates for the quarter have risen 5.9% over the last month; however, full-year estimates decreased by 3.5%, and next fiscal year estimates dipped 2.7% recently, resulting in a Zacks Rank of #3 (Hold) which suggests near-term performance may align with the broader market.
Revenue analysis reveals significant growth projections, with consensus sales for the current quarter estimated at $8.18 million, an 818.8% year-over-year increase, and full-year estimates of $34.63 million reflecting an 886.5% jump; historically, the company reported $1.46 million in revenue last quarter with a 67.8% annual increase, though recent results missed consensus expectations by 82.62% on revenue and 12.28% on EPS. Over the last four quarters, CRSP has topped consensus earnings estimates twice and revenue estimates an unspecified number of times, demonstrating a history of occasional outperformance despite current valuation concerns.
Valuation metrics indicate that CRSP trades at a premium relative to its peers, receiving a low Zacks Value Style Score of F based on traditional and unconventional valuation multiples like price-to-earnings and price-to-sales ratios. While the article notes that past earnings surprises suggest potential for future outperformance, the combined Zacks Rank and high valuation score lead to the conclusion that investors should be cautious about immediate market buzz, as the stock may simply perform in line with general market trends in the near term until these fundamental drivers shift favorably. The piece concludes by directing readers to Zacks Investment Research for further analysis and free reports on recommended stocks for the next 30 days.
📉 Shares underperformed the S&P 500 despite recent price gains.
💰 Analysts project a near-term loss but expect future profitability.
🧮 Recent revenue surged significantly but missed Wall Street estimates.
⚖️ Zacks assigns a Hold rating noting high valuation premiums.
🔭 Revenue growth is crucial for sustaining long-term earnings expansion.
📈 CRISPR Therapeutics shares rose 1.4% over the past month, underperforming the S&P 500's 11% gain and the broader Medical-Biotechnology industry's 1% loss.
🤖 The Zacks investment model prioritizes earnings estimate revisions as the primary driver for short-term stock price movements.
📉 For the current quarter, analysts project a loss of $1.11 per share, representing a +14% improvement from the prior-year period.
📈 Full-year consensus earnings estimates stand at -$5.07, reflecting an +116.2% year-over-year change based on revised growth projections.
💰 Estimates for the next fiscal year show a projected profit of $4.35 per share, indicating a +142% increase from last year's figures.
📉 Earnings estimate trends over the last 30 days indicate a -3.5% revision for the current fiscal year and a -2.7% revision for the next fiscal year.
🧮 The reported revenue of $1.46 million in the last quarter represents a +67.8% increase but missed the consensus estimate by -82.62%.
💰 Previous quarterly earnings per share were -$1.28, compared to -$1.58 a year ago, with EPS estimates missing expectations by -12.28%.
⚖️ The company has surpassed consensus EPS estimates twice in the last four quarters but has not topped revenue estimates during that same period.
📉 A Zacks Rank #3 (Hold) has been assigned to CRSP, suggesting it may perform in line with the broader market in the near term.
💸 The stock received an F-grade on the Zacks Value Style Score, indicating it is currently trading at a premium relative to its peers.
🔭 Revenue estimates for the current quarter and next fiscal year are projected to grow significantly by +818.8% and +274.1% respectively.
📊 The article notes that high revenue growth is essential for sustained earnings expansion in biotech companies like CRISPR Therapeutics.
🧬 Zacks Investment Research recommends checking their proprietary analysis tools for deeper insights into valuation metrics before investing.
Bullish Signals
- Quarterly loss improved +14% to -$1.11.
- Full-year estimate rose +21.6% YoY to -$5.07.
- Current quarter revenue surged +818.8% to $8.18M.
- Company outperformed EPS and revenue estimates last four quarters.
- Recent revenue grew +67.8% YoY to $1.46M.
- Forward FY revenue projected at $129.55M (+274.1%).
- Quarterly EPS loss narrowed from -$1.58 to -$1.28.
Risk Factors
- Stock underperformed S&P 500 with only +1.4% vs 11% rise.
- CRISPR Therapeutics missed earnings by -12.28% and revenue by -82.62%.
- Company graded F on valuation, signaling significant premium vs peers.
- Zacks Rank remains #3 (Hold) despite improved future projections.
Bullish Signals
- CRISPR Therapeutics showed significant earnings improvement with an expected loss of $1.11 per share for the current quarter, representing a +14% change from the year-ago quarter.
- The consensus earnings estimate for the fiscal year has improved significantly with a +21.6% year-over-year change to -$5.07, reflecting growing analyst optimism about future profitability.
- Forward-looking revenue estimates are extremely positive, with current quarter sales projected at $8.18 million and a massive +818.8% increase compared to the same period last year.
- The company has demonstrated a history of outperforming consensus on EPS estimates twice over the last four quarters and has also topped revenue estimates during this period.
- Recent reported revenues of $1.46 million grew by +67.8% year-over-year, indicating strong top-line momentum even while operating at a loss.
- Management has shown confidence in future growth as evidenced by forward fiscal year revenue estimates reaching $129.55 million, a +274.1% increase over the prior year.
- The company successfully turned its EPS loss from -$1.58 to -$1.28 in the last reported quarter, narrowing the deficit while still scaling up revenue operations.
Risk Factors
- The stock has significantly underperformed the broader market and its industry peers, gaining only +1.4% over the past month while the S&P 500 rose 11% and the medical-biotech sector lost 1%.
- CRISPR Therapeutics recently posted a negative earnings surprise of -12.28% and revenue missed consensus estimates by -82.62%, indicating potential issues in meeting investor expectations despite high growth projections.
- The company is graded F on valuation metrics, signaling that the stock is trading at a significant premium compared to its peers and potentially overvalued relative to its current financial reality.
- Despite showing improved earnings projections for future periods, the Zacks Rank remains #3 (Hold), suggesting the market expects the stock's near-term performance to merely align with average broader market movements rather than outperform.
Healthcare sector analyst activity is the primary focus of this article, which details new ratings and price targets for three specific stocks: Dexcom (DXCM), Ironwood Pharma (IRWD), and Crispr Therapeutics AG (CRSP). The content provides specific data points regarding Wells Fargo analyst recommendations for each company. For Dexcom, Wells Fargo analyst Larry Biegelsen maintained a Buy rating with a $85 price target, noting the stock closed at $59.48; however, there is noted conflict among analysts as Dexcom recently saw price targets lowered to ranges of $77-$79 by Citi and Baird in other reports mentioned in the text, with an overall consensus of Strong Buy implying a 33% upside. For Ironwood Pharma, analyst Mohit Bansal maintained a Hold rating at $5 despite a general Moderate Buy consensus suggesting a 61.6% upside to a $7.50 price target. Regarding Crispr Therapeutics AG, Wells Fargo analyst Yanan Zhu maintained a Hold rating with a $75 price target on shares closing at $52.38, though the broader Street consensus suggests a Moderate Buy with an average price target of $72.31. The article also references conflicting analyst opinions from TD Cowen, which maintained a Hold on Crispr with a significantly lower $45 price target.
The summary focuses exclusively on the financial metrics and analyst actions related to these three tickers, ignoring promotional text urging readers to unlock hedge fund data or links to other unrelated market news such as Roblox or Western Digital earnings mentioned in the footer navigation style of the source text. The article qualifies for retention because all three tickers are central subjects of the analysis provided, rather than being incidental mentions within a generic market overview.
📊 Healthcare stocks Dexcom, Ironwood, and Crispr see mixed analyst ratings and price targets.
💰 Dexcom consensus suggests 33% upside despite recent downward target adjustments from major banks.
⚖️ Ironwood shows 61.6% upside potential while Crispr faces divergent views with significant valuation gaps.
- 📊 Analysts have issued new ratings for healthcare stocks Dexcom (DXCM), Ironwood Pharma (IRWD), and Crispr Therapeutics AG (CRSP).
- 💰 Wells Fargo analyst Larry Biegelsen maintains a Buy rating on Dexcom with a price target of $85.00.
- ⚖️ TipRanks notes that Biegelsen has an average success rate of 46.6% based on his track record.
- 📈 Dexcom currently has a Strong Buy consensus with an average price target of $80.50, representing a 33% upside.
- ⛏️ Wells Fargo analyst Mohit Bansal maintains a Hold rating on Ironwood Pharma with a price target of $5.00.
- 🚀 The analyst consensus for Ironwood Pharma is Moderate Buy with an average target of $7.50, implying 61.6% upside.
- ⬇️ Wells Fargo analyst Yanan Zhu maintains a Hold on Crispr Therapeutics AG with a price target of $75.00.
- 🌟 Zhu holds a 5-star analyst rating with an average return of 18.3% according to TipRanks data.
- 🏥 The general street consensus for Crispr Therapeutics AG is Moderate Buy with a $72.31 price target.
- 🤖 TD Cowen maintained a Hold rating on Crispr with a significantly lower price target of $45.00.
- 📉 Citi recently lowered its Dexcom price target from $84 to $79.
- 📈 Baird adjusted its Dexcom price target downward from $87 to $80.
- ⬇️ Bernstein also reduced its Dexcom price target from $83 to $77.
- 💸 The article includes various promotional links for TipRanks services and portfolio management tools.
- 🗂️ Wells Fargo analyst Larry Biegelsen covers other healthcare stocks such as Anteris and Bausch + Lomb.
- 🔬 Mohit Bansal focuses on peers like Mineralys Therapeutics, BioMarin, and Vertex Pharmaceuticals.
- 🧬 Yanan Zhu has experience covering NewAmsterdam Pharma, Atrium Therapeutics, and Iovance Biotherapeutics.
- 📰 This content is a syndicated press release that has not been reviewed or endorsed by the publication.
Bullish Signals
- Dexcom has a Strong Buy consensus with a $80.50 target, implying 33% upside.
- TipRanks upgraded Dexcom to Buy with a $73.00 price target on April 20.
- Ironwood Pharma trades at a discount with a $7.50 target, showing 61.6% upside.
- Crispr Therapeutics holds a Moderate Buy consensus with a $72.31 average target.
- Yanan Zhu is a top-tier analyst maintaining a Hold rating on Crispr Therapeutics.
Risk Factors
- TD Cowen holds Crispr at low $45 target vs market $72 average.
- Wells Fargo holds Crispr at $75 despite recent drop below targets.
- Conflicting analyst views on healthcare names create investment uncertainty.
- Ironwood shows massive divergence between 61.6% consensus upside and TD hold.
Bullish Signals
- Dexcom has a Strong Buy analyst consensus with an average price target of $80.50, representing a 33.0% upside from its current trading levels.
- TipRanks upgraded Dexcom to a Buy rating with a $73.00 price target in a report issued on April 20.
- Ironwood Pharma trades at a significant discount to analyst expectations, with a consensus average price target of $7.50 implying a 61.6% upside from current levels.
- The analyst covering Ironwood Pharma is a highly-rated 5-star analyst with an impressive 9.8% average return and a 56.1% success rate.
- Crispr Therapeutics AG has a Moderate Buy consensus rating with an average price target of $72.31, indicating a 37.5% upside potential from current levels.
- Wells Fargo analyst Yanan Zhu is a top-tier 5-star analyst with an exceptional 18.3% average return who maintains a Hold rating on Crispr Therapeutics AG.
Risk Factors
- TD Cowen maintained a Hold rating on Crispr Therapeutics AG with a low price target of $45.00, significantly below the market's moderate buy consensus average of $72.31.
- Wells Fargo analyst Yanan Zhu assigned a Hold rating to Crispr Therapeutics AG with a $75.00 price target, which is lower than the company's recent trading closure at $52.38 and below broader market optimism.
- The article presents conflicting views from analysts across Dexcom, Ironwood Pharma, and Crispr Therapeutics, creating uncertainty rather than clear investment conviction for these healthcare names.
- For Ironwood Pharma, the disparity between the analyst consensus moderate buy (61.6% upside) and TD Cowen's hold rating ($4.50 target vs current $4.67) suggests significant divergence in analyst outlooks.
CRISPR Therapeutics AG (CRSP) reported first-quarter earnings that missed both analyst estimates for loss and revenue. The company posted an adjusted loss of $1.28 per share, compared to the consensus expectation of a $1.14 loss and its own prior period's loss of $1.58. Revenue came in at $1.46 million, significantly below the estimated $1.79 million (an 82.62% miss), marking the fourth consecutive quarter where the company failed to beat revenue expectations.
This earnings surprise represents a -12.39% miss versus consensus, following a similar miss of -19.13% in the previous quarter's adjusted loss. Although CRSP had outperformed estimates twice in the last four quarters, the consistent failure to meet revenue targets is a notable trend. Since the start of the year, CRSP shares have declined by approximately 1.5%, underperforming the S&P 500 which rose 5.6%.
Looking ahead, analysts expect continued challenges for the biotech sector, with the Zacks Medical - Biomedical and Genetics industry currently ranked in the bottom 44% of all tracked industries. For the upcoming quarter, the consensus EPS estimate is -$1.19 on projected revenues of $8.67 million, while the full-year fiscal estimate stands at a loss of -$4.93 on $35.78 million in revenue. Consequently, Zacks Investment Research maintains a Zacks Rank of #3 (Hold) for CRSP, suggesting shares are expected to perform roughly in line with the market pending further guidance from management regarding future earnings outlooks and industry tailwinds.
🔻 CRISPR posted a $1.28 loss, missing revenue estimates by 82.62%.
📉 Stock underperforms the market while analysts expect continued quarterly losses.
⚠️ The biomedical industry ranks bottom 44% and lacks strong growth signals.
- 🔻 CRISPR Therapeutics AG reported a Q1 loss of $1.28 per share, missing the Zacks consensus estimate of -$1.14.
- 📉 The earnings surprise for the quarter was -12.39%, following a previous quarter's surprise of -19.13%.
- 💸 Revenue reached $1.46 million for the quarter ended March 2026, falling significantly short of the consensus by 82.62%.
- 📊 The company has failed to beat consensus revenue estimates in any of the last four consecutive quarters.
- 📈 Despite posting a loss, adjusted Q1 earnings show an improvement year-over-year compared to a loss of $1.58 per share last year.
- 🔜 Management commentary on the upcoming earnings call will likely be the primary driver for future stock price movement.
- ⚠️ Shares have underperformed the market with a 1.5% decline this year, contrasting against the S&P 500's 5.6% gain.
- 📉 The current Zacks Rank is #3 (Hold), suggesting shares are expected to perform in line with the broader market near-term.
- 📅 Analysts expect losses of -$1.19 per share for the coming quarter and -$4.93 per share for the full fiscal year.
- 🏥 The parent "Medical - Biomedical and Genetics" industry is ranked in the bottom 44% of all Zacks-ranked industries.
- 🔭 Upcoming peer Immunome, Inc. (IMNM) is expected to report a quarterly loss of $0.60 with revenues down 31.7%.
- 📈 Research indicates that top-ranked industries historically outperform bottom-ranked ones by a factor of more than two to one.
- 📝 Investors are advised to monitor earnings estimate revisions as they correlate strongly with short-term stock price trends.
- 🆓 The article concludes with promotional links for free stock analysis reports and Zacks investment research recommendations.
Bullish Signals
- Revenue grew YoY from $0.87M to $1.46M.
- Company beat EPS estimates twice in last four quarters.
- YoY loss narrowed from $1.58 to $1.28 per share.
Risk Factors
- Quarterly loss of $1.28 missed estimates by 12.39%.
- Revenue missed consensus by 82.62% for four quarters.
- Shares underperformed S&P 500, losing 1.5% YTD vs 5.6% gain.
- Zacks Rank #3 indicates mixed estimates and market alignment.
- Industry ranks bottom 44% with no clear positive drivers.
Bullish Signals
- Year-over-year revenue grew from $0.87 million to $1.46 million, demonstrating top-line growth despite missing estimates.
- Over the last four quarters, the company has surpassed consensus EPS estimates on two occasions, indicating periods of positive earnings performance.
- The year-over-year loss narrowed from $1.58 per share to $1.28 per share, reflecting an improvement in quarterly profitability compared to the same period last year.
Risk Factors
- CRISPR Therapeutics reported a quarterly loss of $1.28 per share, missing the consensus estimate of $1.14 by 12.39%.
- The company failed to beat revenue estimates for four consecutive quarters, with Q1 revenues of $1.46 million missing the consensus by 82.62%.
- Shares have underperformed the market significantly, losing approximately 1.5% year-to-date compared to the S&P 500's gain of 5.6%.
- The stock carries a Zacks Rank #3 (Hold) based on mixed estimate revisions and expectations to perform in line with the market rather than outperforming.
- CRISPR Therapeutics trades in the 'Medical - Biomedical and Genetics' industry, which is currently ranked in the bottom 44% of all Zacks industries.
- Future stock performance relies heavily on management's commentary, as there are no clear positive drivers to offset the recent earnings miss.
Morningstar, Inc. (NASDAQ: MORN) has announced a significant rebranding milestone following its acquisition of the Center for Research in Security Prices (CRSP) from the University of Chicago. The company will officially rename the CRSP Market Indexes to Morningstar Indexes, effectively integrating these assets into its existing family of indexes. This strategic move solidifies Morningstar’s position as a top-tier index provider and marks a major step in the integration process that began with the acquisition completed in February 2026.
The renamed indexes serve as critical benchmarks for over $3 trillion in U.S. equities, underpinning a vast array of popular mutual funds and ETFs. Notably, the rebranding affects products managed by industry giants such as Vanguard, including the Vanguard Total Stock Market Index Fund (VTSAX, VTI), Vanguard Mid-Cap Index Fund (VIMAX, VO), and the Vanguard Total Stock Market ETF. The specific example provided is the CRSP US Total Market Index, which will transition to becoming the Morningstar US Total Market Index. This expansion increases the total assets linked to Morningstar’s benchmarks to over $4.2 trillion across more than 370 investment products.
The name change is scheduled to become effective in late July 2026, with a full list of affected indexes available for review. Crucially, Morningstar has assured investors that the methodology behind these indexes will remain unchanged and there will be no disruption to clients or financial performance during the transition. The company emphasized that this acquisition brings renowned data products and academic rigor into its portfolio, uniting two trusted sources of market insight under a shared commitment to transparency and investor-focused solutions.
In statements released alongside the announcement, Morningstar CEO Kunal Kapoor described the addition of CRSP as furthering their efforts to disrupt the costly entrenched index industry by delivering more value at a global scale. Amelia Furr, president of Morningstar Indexes, highlighted that this rebrand represents another step in growing global visibility for the high-quality methodology. The company continues its collaboration with Vanguard and aims to extend its reach across a broader set of clients within the investing ecosystem, while maintaining its commitment to providing efficient, low-cost, high-quality index-based investment strategies.
🚀 Morningstar rebrands CRSP benchmarks, now covering over $3 trillion in U.S. equities.
✏️ Fund names change by late July while underlying tracking methodology remains identical.
🤝 The move strengthens ties with Vanguard to lower costs and improve investor value.
📈 Morningstar has officially rebranded its acquired CRSP Market Indexes under the Morningstar brand name, solidifying its status as a top-tier index provider.
💰 The CRSP benchmarks now cover over $3 trillion in U.S. equities and are linked to more than 4.2 trillion in assets across 370 investment products globally.
🔄 Major funds such as the Vanguard Total Stock Market Index Fund (VTSAX/VTI) and Vanguard Mid-Cap Index Fund will see their underlying indexes renamed from CRSP to Morningstar by late July.
✅ All name changes are cosmetic only; the underlying methodology for tracking market cap, investment style, and sector coverage remains unchanged with no client disruption.
🤝 Morningstar CEO Kunal Kapoor highlighted the strategic goal to disrupt the costly index industry and deliver more value at a global scale to benefit investors.
🤝 The company emphasized its continued collaboration with Vanguard, which shares a mission of providing efficient, low-cost, high-quality index-based investment strategies.
📉 CRSP indexes are favored by the investment community, popularized by the late Jack Bogle, for their comprehensive "total market" coverage that helps lower transaction costs.
📊 Amelia Furr, president of Morningstar Indexes, noted this move enhances global visibility for the high-quality methodology and strengthens Morningstar's position as an alternative to legacy index providers.
🔬 In addition to the benchmark indexes, CRSP’s Research Data Products have been integrated into Morningstar’s family to enhance equity benchmark and data capabilities with academic rigor.
🌍 Morningstar operates through wholly-owned subsidiaries in 32 countries and offers data and research insights across managed investment products, private capital markets, and debt securities.
💼 As of September 30, 2025, the parent company reported approximately $369 billion in assets under management via its investment advisory subsidiaries.
📅 The acquisition of CRSP was completed in February 2026, bringing renowned research data products alongside the established market indexes into Morningstar's portfolio.
🛡️ Both organizations share a commitment to transparency, quality, and investor-focused solutions, reinforcing their shared values within the financial ecosystem.
🌐 Investors seeking more information on the new branding and index families can visit the dedicated website at indexes.morningstar.com.
📢 The press release includes standard forward-looking statements regarding future events or financial performance subject to certain risks and uncertainties.
Bullish Signals
- Morningstar acquired CRSP adding over $3 trillion in AUM.
- Company now manages $4.2 trillion across 370 investment products.
- Leading provider of broad US-equity benchmarks for retirement plans.
- Continues collaboration with Vanguard to offer respected CRSP indexes.
- Acquisition enhances equity benchmark capabilities with renowned research data.
Risk Factors
- Rebranding effective late July creates market timing uncertainty.
- Report omits new vs existing assets, obscuring acquisition impact.
- M&A faces regulatory scrutiny or approval delays risk.
- Actual performance may differ significantly from expectations.
Bullish Signals
- Morningstar has solidified its position as a top-tier index provider following the acquisition of CRSP, bringing over $3 trillion in assets under management (AUM) into the Morningstar Indexes family.
- The company now manages over $4.2 trillion in assets linked to its benchmarks, encompassing more than 370 investment products.
- Morningstar is becoming the leading provider of broad US-equity benchmarks that cover the entire market and serve as the mainstay of retirement plans in the US.
- The rebranding allows Morningstar to continue building on a collaboration with Vanguard to offer highly respected CRSP market indexes and data sets to an even broader set of clients.
- Morningstar is committed to scaling its U.S. index capabilities and extending its reach to more clients across the market and investing ecosystem.
- The acquisition of CRSP enhances Morningstar's equity benchmark and data capabilities with renowned research data products known for their academic rigor, historical depth, and accuracy.
- The combined offering unites two trusted sources of market insight, reinforcing a shared commitment to transparency, quality, and investor-focused solutions.
Risk Factors
- The rebranding of CRSP indexes will only take effect in late July, creating a period of uncertainty regarding market timing for investors and asset managers who may prefer to adjust portfolios earlier.
- While the press release claims over $4.2 trillion in assets are linked to benchmarks, it does not specify how much of this is newly acquired versus existing Morningstar assets, potentially obscuring the immediate financial impact of the CRSP acquisition.
- The integration of CRSP into the Morningstar Indexes family could face regulatory scrutiny or approval delays given the significant market share implications, particularly in a consolidated index provider landscape.
- Morningstar's forward-looking statements explicitly warn that actual performance may differ significantly from expectations due to uncertain factors not currently known.
